Senate Democrats are set to introduce legislation requiring US Health Secretary RFK Jr. to disclose terms of the Trump administration's confidential "most favoured nation" drug pricing deals with 16 pharma companies, according to Axios
- The bill stands little chance of advancing, Axios says, but challenges administration transparency
- Democrats argue that the deals offer minimal patient savings, and largely exclude Medicare and private insurance recipients
Context
This proposed legislation aims to enhance transparency in drug pricing agreements made during the Trump administration but is unlikely to progress. While it highlights concerns over patient savings and exclusions from major programs, the actual impact on the pharmaceutical sector may be muted due to the bill's limited chances of advancing, thus making it a more political statement than a regulatory threat.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#EQUITIES#ENERGY#EU SESSION#WTI#COMMODITIES#INSURANCE#INSURANCE (GROUP)#DXY#TRUMP#TRADE